IP Verse

Methods Of Administering An Egfr Inhibitor - EP2608792

The patent EP2608792 was granted to Boehringer Ingelheim on Oct 11, 2017. The application was originally filed on Aug 24, 2011 under application number EP11752700A. The patent is currently recorded with a legal status of "Revoked".

EP2608792

BOEHRINGER INGELHEIM
Application Number
EP11752700A
Filing Date
Aug 24, 2011
Status
Revoked
Jun 20, 2024
Publication Date
Oct 11, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERJul 11, 2018HAMM & WITTKOPPADMISSIBLE
GENERICS UKJul 11, 2018FRKELLYADMISSIBLE
FRESENIUS KABI DEUTSCHLANDJul 9, 2018FRESENIUS KABI DEUTSCHLANDADMISSIBLE
TEVA PHARMACEUTICALSJul 3, 2018KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP20090160202
DESCRIPTIONWO2010EP50338
DESCRIPTIONUS2003225079
DESCRIPTIONUS2005043233
DESCRIPTIONUS2006058311
DESCRIPTIONUS2009306101
DESCRIPTIONUS2009318480
DESCRIPTIONUS6002008
DESCRIPTIONUS6251912
DESCRIPTIONUS7019012
DESCRIPTIONWO0250043
DESCRIPTIONWO2004074263
DESCRIPTIONWO2005037824
DESCRIPTIONWO2007085638
DESCRIPTIONWO2008121467
DESCRIPTIONWO2009147238
DESCRIPTIONWO2011003853
INTERNATIONAL-SEARCH-REPORTUS2009318480
OPPOSITIONUS2009306101
OPPOSITIONUS37717710P
OPPOSITIONWO2008034776
OPPOSITIONWO2012027445

Non-Patent Literature (NPL) Citations (58) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- A. B. SCHREIBER ET AL., J. BIOL. CHEM., (1983), vol. 258, pages 846 - 853
DESCRIPTION- BRITISH JOURNAL OF CANCER, vol. 98, no. 2008, pages 80 - 85
DESCRIPTION- CARPENTER ET AL., ANN. REV. BIOCHEM., (1987), vol. 56, pages 881 - 914
DESCRIPTION- DAVID W. FRY, PHARMACOL. THER., (1999), vol. 82, no. 2-3, pages 207 - 218
DESCRIPTION- DAVID W. FRY, PHARMACOL. THER., (1999), vol. 82, no. 2-3, pages 209 - 211
DESCRIPTION- DEBONO, ROWINSKY, BR. MED. BULL., (2002), vol. 64, pages 227 - 254
DESCRIPTION- DRUGS OF THE FUTURE, (2008), vol. 33, no. 8, pages 649 - 654
DESCRIPTION- FERRY DR ET AL., EUR J CANCER., (199606), vol. 32A, no. 6, pages 1070 - 1081
DESCRIPTION- HUMPHREY ET AL., PNAS (USA, (1990), vol. 87, pages 4207 - 4211
DESCRIPTION- J. CLIN. ONCOL., (2006), vol. 24, no. 20, pages 3245 - 3251
DESCRIPTION- J. NAT. CANCER INST., (2000), vol. 92, no. 3, pages 205 - 216
DESCRIPTION- Journal of Clinical Oncology, ASCO ANNUAL MEETING PROCEEDINGS, (2006), vol. 24
DESCRIPTION- JURANKA PF ET AL., FASEB J., (198912), vol. 3, no. 14, pages 2583 - 2592
DESCRIPTION- KOBAYASHI, NEW ENGLAND JOURNAL MEDICINE, (2005), vol. 352, page 786
DESCRIPTION- KWAK, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF THE UNITED STATES, (2005), vol. 102, page 7665
DESCRIPTION- LI, D. ET AL., ONCOGENE, (2008), vol. 27, pages 4702 - 4711
DESCRIPTION- LYNCH, NEW ENGLAND JOURNAL MEDICINE, (2004), vol. 350, page 2129
DESCRIPTION- MUKHERJI, D. ET AL., EXPERT OPIN. INVESTIG. DRUGS, (2009), vol. 18, no. 3, pages 293 - 300
DESCRIPTION- PAEZ, SCIENCE, (2004), vol. 304, page 1497
DESCRIPTION- PAO, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF THE UNITED STATES, (2004), vol. 101, page 13306
DESCRIPTION- PATEL, KRUPA J., BMC CANCER, (2009), vol. 9, page 356
DESCRIPTION- S. COHEN ET AL., J. BIOL. CHEM., (1980), vol. 255, pages 4834 - 4842
DESCRIPTION- UEDA K. ET AL., "The human multidrug resistance (mdrl) gene. cDNA cloning and transcription initiation", J. BIOL. CHEM., (198701), vol. 262, no. 2, pages 505 - 508
DESCRIPTION- W. J. GULLICK ET AL., CANCER RES., (1986), vol. 46, pages 285 - 292
INTERNATIONAL-SEARCH-REPORT- CHEN H X ET AL, "Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions", CURRENT PROBLEMS IN CANCER, MOSBY, ST LOUIS, MO, US, vol. 33, no. 4, ISSN 0147-0272, (20090701), pages 245 - 294, (20091215), XP026803866 [X] 21 * the whole document * [Y] 1-24
INTERNATIONAL-SEARCH-REPORT- COLLINS D M ET AL, "Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, (20090605), vol. 28, no. 4, ISSN 1573-0646, pages 433 - 444, XP019816878 [Y] 1-24 * abstract *
INTERNATIONAL-SEARCH-REPORT- LAACK E ET AL, "Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 69, no. 3, ISSN 0169-5002, (20100901), pages 259 - 264, (20100619), XP027172036 [XP] 21 * abstract * * page 262, column 2, paragraph 2 * * table 1 * [Y] 1-24
INTERNATIONAL-SEARCH-REPORT- LIN ET AL, "Drug-drug interaction mediated by inhibition and induction of P-glycoprotein", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 55, no. 1, ISSN 0169-409X, (20030121), pages 53 - 81, (20030121), XP027110081 [Y] 1-24 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MINKOVSKY N ET AL, "BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, (20081201), vol. 9, no. 12, ISSN 1472-4472, pages 1336 - 1346, XP009129910 [X] 21 * abstract * * page 1338, column 2, paragraph 4 - page 1339, column 1, paragraph 3 * [Y] 1-24
INTERNATIONAL-SEARCH-REPORT- VAN ERP N P ET AL, "Clinical pharmacokinetics of tyrosine kinase inhibitors", CANCER TREATMENT REVIEWS, SAUNDERS, US, vol. 35, no. 8, ISSN 0305-7372, (20091201), pages 692 - 706, (20090905), XP026774941 [Y] 1-24 * page 699, column 2, paragraph 4 - column 2, paragraph 3 * * page 700, column 1, paragraph 2 * * page 700, column 2, paragraphs 2,3 * * page 701, column 2, paragraph 2 * * table 4 *
INTERNATIONAL-SEARCH-REPORT- MEDINA P J ET AL, "Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 30, no. 8, doi:10.1016/J.CLINTHERA.2008.08.008, ISSN 0149-2918, (20080801), pages 1426 - 1447, (20080801), XP025430103 [X] 1-5,10-14,19-24 * abstract * * page 1431, column 2, paragraph 5 - page 1432, column 1, paragraph 3 * * table II * [Y] 1-24
INTERNATIONAL-SEARCH-REPORT- CHHUN STEPHANIE ET AL, "Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY AUG 2009 LNKD- PUBMED:19694743, (200908), vol. 68, no. 2, ISSN 1365-2125, pages 226 - 237, XP002666080 [Y] 1-24 * abstract * * page 231, column 2, paragraph 2 *
INTERNATIONAL-SEARCH-REPORT- AGARWAL SAGAR ET AL, "Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (201007), vol. 334, no. 1, ISSN 0022-3565, pages 147 - 155 URL, XP002666082 [Y] 1-24 * abstract *
INTERNATIONAL-SEARCH-REPORT- SWAISLAND H C ET AL, "PHARMACOKINETIC DRUG INTERACTIONS OF GEFITINIB WITH RIFAMPICIN, ITRACONAZOLE AND METOPROLOL", CLINICAL PHARMACOKINETICS, ADIS INTERNATIONAL LTD., AUCKLAND, NZ, (20050101), vol. 44, no. 10, doi:10.2165/00003088-200544100-00005, ISSN 0312-5963, pages 1067 - 1081, XP009056412 [Y] 1-6,10-15,19-24 * abstract * * figure 1 * * tables V, VII *
OPPOSITION- A. SRIRANGAM et al., "Abstract 5503: Small interfering RNA targeting survivin specifically sensitizes non- small cell lung cancer cells to the HIV protease inhibitor ritonavir", Proc. Amer. Assoc. Cancer Res, (20060400), vol. 47, XP055510359
OPPOSITION- BALAYSSAC et al., "Does inhibition of P-glycoprotein lead to drug-drug interactions?", Toxicol Lett., (20050428), vol. 156, no. 3, pages 319 - 329, XP027622211
OPPOSITION- CHEN et al., "Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions", Current Problems in Cancer, St Louis, MO, US, (20090701), vol. 33, no. 4, ISSN 0147-0272, pages 245 - 294, XP026803866
OPPOSITION- COLLINS et al., "Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines", Investigational New Drugs, (20100800), vol. 28, no. 4, ISSN 0167-6997, pages 433 - 444, XP019816878
OPPOSITION- D. BALAYSSAC et al., "Does inhibition of P-glycoprotein lead to drug-drug interactions?", Toxicology Letters, (20050428), vol. 156, no. 3, pages 319 - 329, XP027622211
OPPOSITION- EMA, "EPAR summary for the public on Norvir (ritonavir)", EMA, (20150700), pages 1 - 3, XP055510367
OPPOSITION- EMEA, "Note for Guidance on the Investigation of Drug Interactions", EMEA CPMP/EWP/560/95, (19971217), pages 1 - 13, XP055510360
OPPOSITION- EMEA, "Note for Guidance on the Investigation of Drug Interactions", EMEA CPMP/EWP/560/95, (19971217), pages 1 - 13, XP055510495
OPPOSITION- European Medicines Agency, "Guideline on the Investigation of Drug Interactions", CPMP/EWP/560/95/Rev. 1 - Corr., (20100422), pages 1 - 38, URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf, XP055509801
OPPOSITION- HIRSH, "Afatinib (BIBW 2992) development in non-small-cell lung cancer", Future Oncology, vol. 7, no. 7, (20110706), pages 817 - 825, URL: https://doi.orq/10.2217/fon.11.62, XP055510431
OPPOSITION- "Importance of P-glycoprotein for Drug-Drug Interactions", GLAESER H., Drug transporters. Handbook of Experimental Pharmacology, Springer-Verlag, (20101026), vol. 201, pages 285 - 297, XP055510447
OPPOSITION- J. H. LIN et al., "Role of P-Glycoprotein in Pharmacokinetics", Clinical Pharmacokinet, (20030100), vol. 42, no. 1, pages 59 - 98, XP009154531
OPPOSITION- LIN et al., "Drug-drug interaction mediated by inhibition and induction of P- glycoprotein", Advanced Drug Delivery Reviews, Amsterdam, NL, (20030121), vol. 55, no. 1, ISSN 0169-409X, pages 53 - 81, XP027110081
OPPOSITION- MINKOVSKY et al., "BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors", Current Opinion in Investigational Drugs, US, (20081201), vol. 9, no. 12, ISSN 1472-4472, pages 1336 - 1346, XP009129910
OPPOSITION- N. MINKOVSKY et al., "BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors", Curr. Opin. Investig. Drugs, (20081200), vol. 9, no. 12, pages 1336 - 1346, XP009129910
OPPOSITION- Petra Zagermann-Muncke, "Wenn Arzneistoffe Transportprotein beeinflussen", Pharmazeutische Zeitung, (20060000), pages 1 - 5, URL: https://www.pharmazeutische-zeitung.de/index.php?id=2381, XP055510380
OPPOSITION- TANIGAWARA Y., "Role of P-glycoprotein in drug disposition", Therapeutic Drug Monitoring, (20000200), vol. 22, no. 1, pages 137 - 140, XP002436825
OPPOSITION- T. A. YAP et al., "Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients with Advanced Solid Tumors", Journal of Clinical Oncology, (20100901), vol. 28, pages 3965 - 3972, XP05510356
OPPOSITION- VAN ERP et al., "Clinical pharmacokinetics of tyrosine kinase inhibitors", Cancer Treatment Review s, US, (20091201), vol. 35, no. 8, ISSN 0305-7372, pages 692 - 706, XP026774941
OPPOSITION- YAP et al., "Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor in Patients With Advanced Solid Tumors", Journal of Clinical Oncology, (20100901), vol. 28, no. 25, pages 3965 - 3972, XP055510491
OPPOSITION- MEDINA et al., "Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases", Clinical Therapeutics, Princeton, Nj, US, (20080801), vol. 30, no. 8, ISSN 0149-2918, pages 1426 - 1447, XP025430103
OPPOSITION- CHHUN et al., "Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers", British Journal of Clinical Pharmacology, (20090800), vol. 68, no. 2, ISSN 1365-2125, pages 226 - 237, XP002666080
OPPOSITION- J. CADRANEL et al., "Lung cancer in HIV infected patients: facts, questions and challenges", Thorax, (20061100), vol. 61, no. 11, pages 1000 - 1008, XP055510355
OPPOSITION- SWAISLAND et al., "Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol", Clinical Pharmacokinetics, Auckland, NZ, (20050101), vol. 44, no. 10, ISSN 0312-5963, pages 1067 - 1081, XP009056412

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents